Every Patient Deserves
Complete Evidence
Genomenon structures the biomedical literature into the real-world evidence precision medicine programs and molecular labs need.
More Patients. Expanded Labels. Confident Diagnoses.
The Evidence Already Exists. Getting to It Is the Hard Part.
The evidence to recognize the disease, classify the genetic variant, and reach the patient is already in the publsihed biomedical literature. The challenge is finding it.
Across 11.2 million full-text articles and 3.7 million supplemental datasets, the citation that would change the decision in front of your team is buried in a paper standard tools can't read deeply enough.
When the evidence stays hidden, the cost lands on patients:
- For drug development teams: Genetic variants are left out of the label. Patient populations look smaller than they are. Regulatory files are built on the evidence that was easy to find, not the complete evidence your label demands.
- For molecular labs: A VUS that should have been classified. Case sign-outs stall, get sent for review, or remain unanswered. Diagnoses arrive later than the right evidence would have otherwise allowed.
Genomenon's 3-Step Process
From Hidden Evidence to a Confident Decision
1
Identify
Our AI reads every word of millions of articles and data sources from the biomedical literature.
2
Structure
Our scientists analyze and structure the relevant patient-level evidence.
3
Curate
Our scientists analyze and curate the data to deliver traceable, regulatory-grade evidence at scale.
End Result
Your Teams Can Make Confident Decisions Based on the Complete Set of Evidence Available.
Global Literature
18,000
journals
11.2M
full-text articles
3.7M
supplemental tables and datasets
Sign Out Cases with the Citation Already Pulled
Mastermind and CKB give your variant interpretation team AI-powered literature search and expert-curated evidence at the variant level. Fewer VUS. Faster turnaround. A diagnosis on cases that used to stall.
Build Your Drug Program with Complete Evidence
Custom real-world evidence builds give your team the variant, patient, and prevalence picture your program decisions depend on. Broader labels. More eligible patients. Programs you can defend in front of regulators.
Trusted by Industry Leaders Including
"Genomenon’s innovative approach to leveraging literature for real-world evidence significantly enhanced our understanding of ENPP1 Deficiency."
Catherine Nester
Senior Vice President, HCP and Patient Engagement at Inozyme Pharma
"By partnering with Genomenon, we are helping to close critical knowledge gaps, accelerate accurate diagnosis, and support the global research community in their efforts to bring hope and new possibilities to those affected by TK2d."
Sarah Chang, Ph.D.
Medical Strategy Lead at UCB
"CKB enables comprehensive and reliable interpretation of any genomic test in a fully automated setting. We can rely on never missing relevant variants."
Korneel Duyvesteyn
Development lead at Hartwig Medical Foundation
